key: cord-1003278-gda7asd4 authors: Rajpal, Aman; Rahimi, Leili; Ismail‐Beigi, Faramarz title: Factors Leading to High Morbidity and Mortality of COVID‐19 in Patients with Type 2 Diabetes date: 2020-07-16 journal: J Diabetes DOI: 10.1111/1753-0407.13085 sha: 30edbfc6f4df747d04b95e3769c4b3599b4acc90 doc_id: 1003278 cord_uid: gda7asd4 COVID‐19 is a recent pandemic caused by SARS‐Cov‐2, a novel coronavirus. Diabetes (mostly type 2 diabetes mellitus, T2DM) and hyperglycemia are among the major comorbidities in patients with COVID‐19 leading to poor outcomes. Reports show that patients with diabetes and COVID‐19 are at an increased risk for developing severe complications including acute respiratory distress syndrome (ARDS), multi‐organ failure and death. Here we explore potential mechanistic links that could explain the observed higher morbidity and mortality in this patient population. Patients with T2DM have an underlying increased level of inflammation associated with obesity and insulin resistance in addition to other comorbidities including HTN, obesity, CVD, dyslipidemia and being older. We review evidence that T2DM with hyperglycemia are among factors that lead to elevated expression of ACE2 in lungs and other tissues; ACE2 is the cellular “receptor” and port of viral entry. The pre‐existing chronic inflammation with augmented inflammatory response to the infection and the increasing viral load leads to extreme systemic immune response (“cytokine storm”) that is strongly associated with increased severity of COVID‐19. Based on the available evidence, it is recommended by a panel of experts that safe but stringent control of blood glucose, blood pressure and lipids be carried out in patients with T2DM, measures that could potentially serve to decrease the severity of COVID‐19 should these patients contract the viral infection. Once the infection occurs, then attention should be directed to proper glycemic control with use of insulin and frequent monitoring of blood glucose levels. In December 2019, Wuhan City in Hubei Province of China experienced an outbreak of pneumonia caused by a novel coronavirus SARS-Cov-2, and the disease was subsequently named COVID-19. 1,2 This highly infectious RNA virus has now spread to many parts of the world causing ever-increasing morbidity and mortality. The protein envelope of the virus contains "crown like" spike projections (S protein) that binds to angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase that is expressed on the surface of pulmonary epithelial and alveolar cells as well as many other cells throughout the body; ACE2 mediates the internalization of the virus following the action of transmembrane serine protease 2 (TMPRRSS2). 3, 4 Following intracellular replication, the virus stimulates humoral and cellular immunity pathways, and in severe cases leads to a strong inflammatory and hyper-immune response ("cytokine storm") that can cause massive bilateral viral pneumonia, acute respiratory distress syndrome (ARDS), cardiac and kidney injury, hyper-coagulation and strokes, liver damage, infection of pancreatic islets, and multiple organ failure. 5 The spectrum of symptoms of COVID-19 spans from being asymptomatic to having a mild upper respiratory tract infection or diarrhea, to severe illness. 6 A high percentage of severely ill patients have one to several pre-existing comorbidities including increased age, hypertension, type 2 diabetes mellitus (T2DM), obesity, dyslipidemia, renal, and cardiovascular disease (CVD). 6, 7 It is not known This article is protected by copyright. All rights reserved. whether patients with T2DM are more vulnerable to contract the infection (as they are to other infections), but it is clear that once infected, they are at high risk for severe disease. 8 This review is focused on patients with T2DM who develop COVID-19. However, many of the aspects of the clinical course of the disease are also applicable to patients with type 1 diabetes mellitus (T1DM), especially older patients who have become overweight or obese and have microvascular and macrovascular disease. Here we explore the factors and pathways that could explain the observed higher morbidity and mortality of patients with T2DM and COVID-19. 9,10 Figure 1 shows the relationship of the common conditions that are present in most patients with T2DM; each of these factors is associated with increased susceptibility for developing severe COVID-19. The diagram illustrates the inter-relationship of multiple factors and how they can collectively contribute to the severity of the disease. We postulate that multiple factors including obesity, pre-existing insulin resistance, hypoglycemia, and the elevated chronic state of inflammation potentially lead to increased susceptibility to develop severe infection with SARS-Cov-2 virus. Increased expression of ACE2 and introduction of the virus through binding to ACE2 in the lungs leads to systemic infection that exacerbates the existing chronic inflammation and leads to an intense immunological reaction which underlies the development of the severe COVID-19. We will briefly discuss these factors and their interrelationships in the following sections. We will also review treatment modalities focused on diabetes and the inflammation/immune response in patients with diabetes and COVID-19. This article is protected by copyright. All rights reserved. Patients with T2DM are not only vulnerable to various infections caused by bacteria and fungi, they also develop more severe illness as compared to patients without diabetes. 11, 12 There are various mechanisms that are possibly responsible for this higher susceptibility and severity of infections. There is impaired polymorphonuclear function, including chemotaxis, adherence, phagocytosis, and intracellular killing, 13 as well as impairment of T-lymphocyte function. 14 Also, there is dysregulation of nitric oxide (NO) production in response to bradykinin leading to vasoconstriction, which could attenuate the ability of phagocytes to reach their targets. 15, 16 T2DM is also associated with decreased host defense immunity, thereby further increasing the susceptibility to infections. 17 Hyperglycemia and hyperinsulinemia can impair complement receptor-3 and Fcg receptormediated phagocytosis in neutrophils by activating protein kinase Ca or protein kinase Cb. 18 Unlike bacterial infections, the physiological response in normal individuals to viral infection and replication is activation of transcription factors including interferon regulator factors (IRFs) and nuclear factor kB (NF-kB). 19, 20 This in turn leads to antiviral response by induction of IFN-I and IFN-III and recruitment of specific subsets of leukocytes stimulated by chemokine secretion. [21] [22] [23] One study showed that patients with T2DM had decreased This article is protected by copyright. All rights reserved. antiviral response demonstrated by a diminished production of IFN-α. 24 Another study performed on human peripheral blood mononuclear cells and human monocyte cell lines in vitro showed that hyperglycemia suppressed IFN-1 production, and that pre-exposure to high glucose concentrations rendered monocytes more sensitive to IFN-α stimulation with heightened signaling. 25 Additionally, they found that high glucose levels promoted the production of other pro-inflammatory cytokines. 25 Therefore, it is probable that patients with T2DM may have alterations in their innate immune system that promotes pro-inflammatory cytokines as well as having a defective host defense system against viral infections by impeding IFN-1 production and signaling. Angiotensin-2 is an 8-amino acid peptide produced by action of angiotensin converting enzyme (ACE1) on angiotensin-1. Angiotensin-2 stimulates aldosterone secretion, increases sodium retention and BP, increases vascular permeability in the lungs thereby increasing the risk for ARDS; it also elicits inflammatory responses. 26,27 Angiotensin converting enzyme-2 (ACE2) is a plasma membrane protein expressed largely in the lungs as well as in many other tissues and endothelial cells including the heart, kidneys, and importantly in insulin producing β-cells. 4,28-30 SARS-CoV-2 virus has a high affinity towards ACE2, and upon binding the virus, the complex is internalized resulting in intracellular replication of the virus; 3 hence, ACE2 acts as the "receptor" for SARS-CoV-2 and is the dominant path of the virus's entry into the lungs and other cells in the body. 4, 31, 32 Expression of ACE2 is increased in patients with diabetes and in response to elevated glucose levels; 4, 29, 33, 34 Hence the balance between ACE1 and ACE2 activity seems to be critical to the outcome of patients suffering from COVID-19, and discontinuation of ACE inhibitors and ARBs is not recommended by many scientific societies and regulatory bodies. 41 Intriguingly, glucocorticoids also attenuate angiotensin 1-7 and Mas receptor expression. 42 Many reports show that T2DM is a frequent pre-existing condition that is associated with severe disease and death in patients with COVID-19. [43] [44] [45] Bode et al reported that patients admitted with COVID-19 with either diabetes or uncontrolled hyperglycemia This article is protected by copyright. All rights reserved. (defined by 2 blood glucoses of >180 mg/dL within a 24h period) had higher mortality and longer hospitalizations. 10 In these patients, those with uncontrolled hyperglycemia had a higher mortality (41.7%) with or without known history of diabetes as compared to 14.8% in patients with controlled diabetes. 10 Similar to reports of the Severe Adult Respiratory Syndrome (SARS) epidemic, 28 a recent study of patients with COVID-19 showed that a fasting plasma glucose ≥126 mg/dL is an independent predictor for in-hospital mortality. 46 Another recent study among 7,300 hospitalized patients with COVID-19 found that although the presence of T2DM was associated with higher mortality, patients with diabetes and poorly controlled glycemia had even higher death rate compared to patients with better controlled blood glucose. 45 Acute (stress) hyperglycemia per se in the setting of severe illness or surgery is associated with longer length of hospital stay, higher infection rates, longer duration of ventilator management, and increased mortality. 47 Stress hyperglycemia occurs in individuals without diabetes and is thought to result from a surge of catecholamines and especially cortisol in response to acute stress. 48 In COVID-19 illness, direct damage of βcells due to entry of the virus through cell surface ACE2 protein can lead to cell damage and apoptosis causing relative insulin deficiency and acute hyperglycemic state. 28, 29 Indeed, new onset diabetes with diabetic ketoacidosis has been described in previously healthy individuals; this may well be due to the β-cell damage induced by the infection. 49, 50 Acute hyperglycemia was also identified as a significant predictor of severity and death in patients infected with 2003 SARS, 2009 pandemic influenza A (H1N1) and MERS-CoV. 28, [51] [52] [53] ACE2 protein is expressed on alveolar cells of the lungs and serves as the site of entry for the virus into the body, 3,31,32 and ACE2 expression is increased in patients with diabetes and in response to hyperglycemia. 29,33,34 Higher expression of "receptor" sites in the pulmonary system could help explain the greater propensity of patients with diabetes and hyperglycemia for developing a more severe disease. Histopathological changes in the lungs of patients with diabetes includes thickened alveolar, epithelial, and pulmonary capillary basal lamina. 54 Hyperglycemia can cause microangiopathy of alveolar capillaries and non-enzymatic glycation of proteins in the lungs. This makes collagen less susceptible to proteolysis, leading to its accumulation in the connective tissue in the lungs and causes restrictive lung disease. The loss of elastic recoil of the lungs leads to collapse of small airways during exhalation. 54, 55 Hyperglycemia also reduces muco-ciliary clearance that can lead to increased lung infection. 56 In addition, insulin resistance and systemic inflammation results in oxidative stress and inflammatory response in the pulmonary system. It can also reduce respiratory muscle strength leading to functional lung abnormality. 54, 56 Finally, high glucose levels promote glycation of proteins and stimulate the synthesis of pro-inflammatory cytokines leading to oxidative stress; in addition, the production of adhesion molecules that mediate tissue inflammation is stimulated. 57 It is also possible that This article is protected by copyright. All rights reserved. ACE2 on the surface of lung epithelial cells or the viral spike protein itself becomes glycated due to the hyperglycemia, thereby altering the binding of the viral spike protein to ACE2 and perhaps magnifying the degree of inflammation and the immune response to the virus. 58 Increasing age was reported as an important independent predictor of mortality in SARS and MERS, 59, 60 and recent data in patients with COVID-19 have shown similar findings. 6 In addition, insulin resistance, CVD, hypertension, T2DM, dyslipidemia, and obesity are more prevalent in the elderly. Age-dependent defects in T-cell and B-cell function and excess production of type 2 cytokines can lead to a deficiency in control of viral replication and more prolonged pro-inflammatory responses, potentially leading to poor outcomes. 61 The above age-related factors are associated with and lead to higher basal levels of chronic inflammation. Multiple reports from China and the US have shown that hypertension is associated with increased prevalence and severity of COVID-19. 36,62-66 A pooled analysis found that This article is protected by copyright. All rights reserved. hypertension is associated with ~2.5-fold increased risk for both severity and mortality in patients with COVID-19. 67 Chronically elevated blood pressure is one of the hallmarks of both the insulin resistant state and T2DM, 68, 69 and hypertension is strongly associated with and can lead to worsening of CVD. 70, 71 High blood pressure is a known risk factor for unfavorable progression of ARDS in patients with pneumonia. 72, 73 Hypertension can also cause a decline in ACE2 expression, 74 and it has been proposed that the interaction of the virus with ACE2 leading to its internalization can reduce the residual surface ACE2. This could lead to increased angiotensin-2 and decreased angiotensin 1-7 levels that can cause worsening of ARDS. 75 Hence, an interplay between hypertension and COVID-19 could lead to a synergistically increased risk for adverse outcomes. Given that hypertension is highly prevalent in patients with T2DM 69 Various reports show a high prevalence of obesity in patients with COVID-19 including data from New York City where out of 5700 patients with COVID-19, 42% were This article is protected by copyright. All rights reserved. obese, 63 and severe obesity (BMI > 40 kg/m 2 ) placed patients at a much higher risk for complications from COVID-19. Among 383 COVID-19 patients in Shenzhen, China, after adjusting for other risk factors, obesity was associated with ~2.4-fold higher odds for developing severe pneumonia, compared to patients with normal weight. 76 Another study from New York City reported that after old age, severe obesity was the second strongest independent predictor for hospitalization (OR of 6.2). 77 Most recently, a detailed study of role of co-morbidities in patients with T2DM who developed severe COVID-19 reported that obesity was the single most important comorbidity that was associated with high rates of ICU admissions and mortality. 78 It is well known that severe obesity increases the risk of ARDS 79 and can lead to difficult intubation in those requiring respiratory support. Possible underlying mechanisms for respiratory failure include impaired breathing mechanics, increased airway resistance and impaired gas exchange with low respiratory muscle strength and lung volumes. 80 Similar to T2DM, obesity with underlying insulin resistance is associated with a state of chronic inflammation that can lead to poor outcomes in patients with Obesity is strongly associated with hypertension, and various mechanisms including activation of the sympathetic nervous system, stimulation of renin-angiotensin system, increased leptin levels, endothelial dysfunction, and renal functional abnormalities causing sodium retention mediate the hypertension in these individuals. 82, 83 Also, obesity-related underlying insulin resistance and heightened inflammatory state are linked to This article is protected by copyright. All rights reserved. hypertension. 68, 84 Hence, the strong association of obesity with hypertension, CVD, insulin resistance and T2DM 85 can further increase the severity of COVID-19. Dyslipidemia is present in 30-60% of patients with T2DM. 86 Dyslipidemia in T2DM is characterized by elevated triglycerides (TGs) in most patients and somewhat elevated LDL and low HDL. 86 Insulin resistance in T2DM is virtually present in all insulin-responsive cells, including adipocytes, where it results in increased release of free fatty acids (FFA) and inflammatory cytokines such as IL-6, TNFα, and leptin. 87 Elevated FFA are taken up by the liver and deposited as triacylglycerols in fat droplets or are secreted as VLDL particles leading to hypertriglyceridemia. The elevated blood TGs derived from VLDL are deposited in skeletal and cardiac muscle, and other insulin-responsive cells and decrease their sensitivity to insulin. Elevated FFA also stimulates atypical protein kinase C (PKC) that inhibits insulin signaling and glucose uptake in skeletal muscle and results in excess gluconeogenesis in the liver. 87, 88 In addition, FFA directly activates Toll-Like Receptor 4 (TLR4), which are mainly expressed on immune system cells including monocytes, macrophages and dendritic cells; activation of this receptor leads to cytokine secretion and inflammatory response. 87,89 TG-rich VLDL slowly loses some of their TG and transform into LDL molecules. In T2DM, the LDL particles are smaller and denser than normal and are more atherogenic. 90, 91 This partly explains the increased premature atherosclerosis and cardiovascular disease in patients with T2DM. 91 The dyslipidemia present in T2DM contributes to the insulin resistant state in a selfreinforcing cycle. The pre-existing inflammatory state associated with dyslipidemia and insulin resistance augment the inflammatory response by SAR-CoV-2 infection. Patients with pre-existing CVD appear to have heightened vulnerability to develop severe COVID-19 illness with worse clinical outcome. 43, 92, 93 In a report of 52 critically ill patients with COVID-19, prevalence of pre-existing CVD was higher in those who did not survive compared to survivors (53% vs 20%). 94 Similarly, another report on fatality with COVID-19 showed a significantly higher rate of pre-existing CVD compared with survivors (24% vs 1%). 6 A meta-analysis of six published studies from China including 1527 patients with COVID-19 reported that the presence of CVD was associated with a 3-fold greater risk for developing severe COVID-19 or requiring ICU admission. 93 Various cardiovascular risk factors, including dyslipidemia, hypertension, insulin resistance and T2DM can adversely affect the prognosis of COVID-19. Many of these factors can lead to a heightened inflammatory state, which could be a potential mechanism underlying the association between COVID-19 and new cardiac events, especially in patients with pre-existing CVD. 95 It is known that inflammatory reaction following pneumonia or ARDS can result in plaque instability causing acute coronary events. 96 The acute inflammatory response may increase the demand for higher cardiac function and sympathetic hyperactivity thereby increasing the risk for arrhythmias and heart failure in patients with COVID-19 and pre-existing CVD. 97 The prevalence of mild to moderate CKD in older patients with established diabetes (aged ≥65 years) ranges from 35-40%. 98 CKD is associated with an increased risk for pneumonia and pneumonia-related mortality. 99,100 ACE2 is highly expressed in renal tubular epithelial cells and less so in glomerular epithelial cells and vasculature. 101 Increase ACE2 leading to direct viral invasion, along with hypercoagulation could possibly explain the high risk of acute kidney injury in patients with COVID-19 even without pre-existing renal disease. 102 A meta-analysis of four studies in 1389 patients showed a 3-fold higher risk for severe COVID-19 in patients with CKD. 103 There is a suggestion that plasma ACE2 activity is increased in patients with CKD, 104,105 but by the time ESRD is reached and dialysis is initiated, a relative deficiency in plasma ACE2 activity ensues. 106 Still, there is higher risk of severe illness in patients on hemodialysis with COVID- 19. 107 This article is protected by copyright. All rights reserved. ACE2 activity has been shown to be altered in diabetes kidney disease (DKD). 105 ACE2 and ACE-1 mRNA and protein expression are altered in mouse models of DKD and in patients with DKD. 108, 109 Thus, patients with DKD, who develop COVID-19 may be at higher risk of acute kidney injury because of upregulation of the ACE-1 and downregulation of ACE2, a combination that can lead to increased angiotensin levels with pro-inflammatory and profibrotic actions in the kidneys. SARS-CoV-2 can directly induce inflammation of vascular endothelial cells following viral entry into endothelial cells via ACE2 receptor. 110 Endothelial damage can activate coagulation pathways, leading to microthrombi in small and large vessels of the lung and other organs. 111 T2DM, hyperglycemia and insulin resistance are associated with endothelial cell dysfunction and stimulate platelet activation and aggregation, changes that lead to hypercoagulable state. 8,112 Elevated pro-inflammatory cytokines in patients with T2DM that are known cause of coagulation activation 113 and endothelial dysfunction may constitute a trigger for pro-coagulant imbalance in patients with COVID-19. Furthermore, poor prognosis of COVID-19 is associated with hypercoagulability and high blood D-dimer levels. 114, 115 In addition, patients who developed acute respiratory failure had This article is protected by copyright. All rights reserved. hyperfibrinogenemia, a known cause of hypercoagulability. 116 In keeping with this are recent reports of blood clot formation in large arterial and venous vessels leading to strokes, especially in relatively young persons with no pre-existing conditions, and the finding of multiple micro-emboli and clots in lungs of patients with COVID-19. 117 Type 2 diabetes is a disorder of beta cell function and insulin resistance of tissues that develops over many years. 118 There are multiple genetic and environmental factors that lead to the development of the disease. There is evidence that the chronic inflammation and dysfunction of the innate immune system play important roles in the pathogenesis of T2DM. 119 CRP, IL-1β, IL-6 and other cytokines are elevated in patients with T2DM, 120 and there is increasing evidence that activation of immune system, high oxidative stress and adipose tissue inflammation are related to pathogenesis and progression of T2DM. 81, 121, 122 Upon infection with SARS-Cov-2 and the increased viral load due to replication of the virus in many cells throughout the body, the pre-existing chronic inflammation is further increased and plays a critical role in the progression of COVID-19. 66,123 A meta-analysis by Zeng et al, evaluated 16 retrospective studies and found that inflammatory markers, especially CRP, procalcitonin, IL-6 and ESR were positively correlated with the severity of COVID-19. 124 Another retrospective, multicenter cohort study, reported a significant elevation of IL-6 in COVID-19 non-survivors, as compared to survivors. 6 In patients with T2DM, macrophages, adipocytes and endothelial cells release proinflammatory cytokines such as TNFα, IL-1, IL-6, and IL-10. 125, 126, 127 T2DM is therefore associated with a general activation of the innate immune system in which there is a chronic cytokine-mediated state of low-grade inflammation. 120, 128 Hyperglycemia also increases the formation of advanced glycation end products (AGEs) that stimulate the production of reactive oxygen species (ROS); this leads to increased oxidative stress and activation of immune response. In addition, high insulin levels can induce an inflammatory reaction. 129 Evidence suggests that SARS-CoV-2 produces a vigorous innate immune response, 130 leading to so called "cytokine storm" that appears to mediate severe disease. "Cytokine storm", a condition without an exact definition, is characterized by a powerful activation of the immune system. It was noted in previous coronavirus pneumonias due to SARS and MERS that circulating levels of pro-inflammatory cytokines such as IFN-γ, IL-1B, IL-6, IL-12 and chemokines such as CXCL10, and CCL2 are increased and are associated This article is protected by copyright. All rights reserved. with pulmonary inflammation and extensive lung damage. 131, 132 Similarly, the "cytokine storm" induced by SARS-Cov-2 infection and the sustained inflammatory response is thought to play a critical role in the high mortality of patients with COVID-19. 43, 133 Lymphocytopenia is one of the prominent markers of COVID-19 and can be used as part of the diagnostic criteria for COVID-19 and its severity. 134 Zhu et al showed that IL-6, CRP and LDH levels were significantly higher in patients with T2DM and COVID-19 during 28-day follow-up as compared to patients with COVID-19 without T2DM. 45 Taken together, presence of T2DM with chronic inflammation and other comorbidities associated with defective immune response, especially the low levels of IFN-1, may allow unrestricted viral replication and trigger high levels of inflammation, hyperimmune reaction and greatly exacerbate the response to SARS-CoV-2. In sum, "cytokine storm" has emerged as potentially the main factor driving the more severe clinical course of COVID-19. It is the advice of an international panel of diabetes experts that in the era of COVID-19, medical management of patients with either T1DM or T2DM should continue with the aim of achieving near-normal levels of blood glucose, BP, and lipids safely considering patient choices and economic factors. 138 It is also advised that stringent control be continued if patients with diabetes develop COVID-19. 138 However, at the present time not enough evidence has been accrued to enable strong recommendations for the use of any specific medications in patients with diabetes and COVID-19. This article is protected by copyright. All rights reserved. Uncontrolled or stress hyperglycemia is associated with increased severity of COVID-19 and mortality. In addition, very high levels of blood glucose often occur as the patient's illness advances and reaches severe levels. Hyperglycemia stimulates the expression of ACE2. Hyperglycemia can also induce glycation of ACE2, which may cause increased entry of SARS-COV-2 into the cells, leading to increased inflammation and hyper-immune responses. 139 Hence, it is essential to closely monitor and manage blood glucose levels in patients hospitalized with diabetes and COVID-19. Glucose-lowering agents, especially insulin, play an important and critical role in management of T2DM under conditions that the disease becomes so severe that beta cells infected with the virus are under stress and may be undergoing apoptosis and cannot release adequate amounts of insulin. In keeping with this, new onset diabetic ketoacidosis has been reported in individuals with severe COVID-19 in the absence of prior history of diabetes. 49, 50 Insulin is the major glucose-lowering agent that can be used in COVID-19. Some oral antidiabetic medications can potentially be effective in alleviating inflammation in patients with T2DM and COVID-19. Metformin and activation of AMPactivated protein kinase (AMPK) 140 increases the expression and phosphorylation of ACE2 141 that may lead to decreased SARS-CoV-2 binding. 142 In addition, metformin reduces the production of reactive oxygen species (ROS), oxidative stress, and DNA damage. 143 This article is protected by copyright. All rights reserved. Sodium-glucose transport inhibitors (SGLT2is) have been reported to increase ACE2 levels, leading to increase in angiotensin 1-7 that has vasodilatory effects and decreases inflammation in the lungs. 144 Additionally, they prevent the release of proinflammatory cytokines in the body. 145, 146 On the other hand, the increase in ACE2 expression may have detrimental effects of the disease severity. Not enough information is available to make a rational judgement. Despite the many on-going studies, not enough large-scale randomized controlled trials using specific agents or treatment modalities have been completed to make informed decisions. While this review is focused on the pathogenesis of severe COVID-19 in patients with T2DM, we will briefly summarize some recent studies directed at treatment of COVID- Lipid ibuprofen has been shown to improve survival in animal models of ARDS by modulation of cytokine responses. 155 However, some investigators raised concerns that This article is protected by copyright. All rights reserved. use of ibuprofen in patients with COVID-19 may increase the activity of ACE-2 that could be harmful. 36,156 Subsequent reviews found no evidence of severe adverse events in patients with COVID-19 as a result of usage of such agents. 157 The on-going LIBERATE trial is testing the effect of three dosages of lipid ibuprofen on progression of lung injury in patients with SARS-CoV-2 infection. 158 Most recently, it has been reported that dexamethasone (used at a dose of 6 mg daily) has a positive effect in patients severely affected with COVID-19 by reducing mortality. 159 Dexamethasone would be expected to increase blood glucose levels, especially in patients with T2DM who already have a high degree of insulin resistance. Nevertheless, it appears that the positive anti-inflammatory and immune modulating effects of the agent overrides the negative effects of hyperglycemia; the elevated glucose levels can by managed by meticulous insulin treatment and careful monitoring. Colchicine may also have positive effects on the course of COVID-19. 160 Uncontrolled "cytokine storm" appears to be the most dangerous and potentially lifethreatening event related to severity of COVID-19. Studies using inhibitors of cytokines including IL-1 and IL-6 are on-going in the management of the hyper-immune reaction in severely ill patients with COVID-19. This article is protected by copyright. All rights reserved. Chloroquine and hydroxyl-chloroquine (HCQ) with immunosuppressive effects are being evaluated as potential treatments for COVID-19. Two large retrospective studies using HCQ have found no beneficial effects in severity of COVID-19 or related mortality; interestingly, more patients in the treatment arm had diabetes. 161, 162 IL-6 appears to play an important role in the pathogenesis of the "cytokine storm". 163, 164 Effects of tocilizumab (TCZ), a humanized anti-IL-6 receptor IgG1 monoclonal antibody, was examined in an uncontrolled study in patients with COVID-19 and ARDS requiring mechanical ventilation; it was found that patients treated with tocilizumab showed a rapid, sustained, and significant clinical improvement. 165 Elevated IL-1 levels are also associated with disease severity. In a retrospective cohort study of patients with less severe COVID-19 and ARDS (not admitted to the ICU), treatment with high-dose anakinra (an IL-1 blocker) was associated with clinical improvement in the majority of patients. 166 Use of dexamethasone (as an immune-modulating agent) in decreasing mortality in severe cases of COVID-19 is described above. In sum, there is increasing evidence that immune-based therapies may improve outcomes of severe COVID-19. Results of more studies, especially focused on patients with T2DM, are anticipated. This article is protected by copyright. All rights reserved. There is a heightened level of inflammation that is chronically present in patients with T2DM prior to being affected with COVOD-19. This is largely due to the multiple conditions that are present in these individuals including older age, HTN, obesity, CVD and dyslipidemia. However, as depicted in Figure 1 , we hypothesize that the chronic inflammation becomes greatly amplified following the infection by the virus. Elevated expression of ACE2 in lungs and other tissues facilitates increased viral entry and viral load thereby greatly stimulating pre-existing inflammation in patients with T2DM. This in conjunction with a hyperactive immune response ("cytokine storm") appears to be the final common pathway leading to severe cases of COVID-19. Based on the available evidence, it is recommended that safe but tight control of blood glucose, HTN, and lipids in patients with T2DM may serve to decrease the severity of COVID-19 illness, should they contract the viral infection. 138 Also, use of continuous glucose monitoring devices (where available), especially in patients admitted to ICU, for frequent glucose monitoring to help adjust insulin therapy is recommended. Finally, recently it has been reported that a daily dose of 6 mg dexamethasone decreases mortality in patients severely affected by COVID-19. 159 The increase in glycemia due to use of the glucocorticoid will require adjustment of insulin therapy. This article is protected by copyright. All rights reserved. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives Epidemiology, Pathogenesis, and Control of COVID-19 Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus Molecular immune pathogenesis and diagnosis of COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical infectious diseases : an official publication of the Infectious Diseases Society of America COVID-19 and diabetes: Knowledge in progress. Diabetes research and clinical practice COVID-19 pandemic, coronaviruses, and diabetes mellitus Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States Infections in Diabetes Mellitus and Hyperglycemia. Infectious Disease Clinics of North America The global diabetes epidemic: what does it mean for infectious diseases in tropical countries? Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function In vivo determination of cell mediated immune response in diabetic patients using a multiple intradermal antigen dispenser The role of nitric oxide in the development of diabetic angiopathy Effects of acute hyperglycemia on endothelium-dependent vasodilation in patients with diabetes mellitus or impaired glucose metabolism Infections in patients with diabetes mellitus: A review of pathogenesis Hyperglycemia-induced protein kinase C activation inhibits phagocytosis of C3b-and immunoglobulin g-opsonized yeast particles in normal human neutrophils Double-Stranded RNA Sensors and Modulators in Innate Immunity The Evolution of Antiviral Defense Systems Shared and Distinct Functions of Type I and Type III Interferons Chemokine receptors: multifaceted therapeutic targets The chemokine system in innate immunity ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 Fetal betamethasone exposure attenuates angiotensin-(1-7)-Mas receptor expression in the dorsal medulla of adult sheep Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes/metabolism research and reviews Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell metabolism Blood glucose is a representative of the clustered indicators of multi-organ injury for predicting mortality of COVID-19 in Wuhan A systematic scoping review on the consequences of stress-related hyperglycaemia Stress hyperglycemia: an essential survival response! Crit Care Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes research and clinical practice Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabetic medicine : a journal of the Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia The diabetic lung--This article is protected by copyright. All rights reserved. a new target organ? Diabetic lung disease: fact or fiction? Reviews in endocrine & metabolic disorders Diabetes and Lung Disease: A Neglected Relationship Leukocyteendothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong Predictors of mortality in Middle East respiratory syndrome (MERS) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: a systematic review and meta-analysis Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Clinical Characteristics of Coronavirus Disease 2019 in China Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: A systematic review and meta-analysis. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): a pooled analysis. Polish archives of internal medicine The inter-relationship between insulin resistance and hypertension Prevalence and coprevalence of comorbidities among patients with type 2 diabetes mellitus. Current medical research and opinion This article is protected by copyright. All rights reserved Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy lifeyears lost, and age-specific associations in 1.25 million people Effect of Systolic and Diastolic Blood Pressure on Cardiovascular Outcomes Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia Risk factors for outcomes of acute respiratory distress syndrome patients: a retrospective study Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Current opinion in nephrology and hypertension Clinical Characteristics of Covid-19 in China. The New England journal of medicine Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study Obesity and respiratory diseases Inflammation, stress, and diabetes Mechanisms of obesity-induced hypertension Insulin Resistance and Hypertension Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans Association between insulin resistance and the development of cardiovascular disease Associations of lipid profiles with insulin resistance and beta cell function in adults with normal glucose tolerance and different categories of impaired glucose regulation Toll-like receptor 4 in acute viral infection: Too much of a good thing Dyslipidemia in diabetes mellitus and cardiovascular disease Diabetes therapy : research, treatment and education of diabetes and related disorders Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory medicine Inflammation and atherosclerosis Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Clinical Manifestations of Kidney Disease Among US Adults With Diabetes Risk of pneumonia among patients with chronic kidney disease in outpatient and inpatient settings: a nationwide population-based study Pulmonary infectious mortality among patients with end-stage renal disease Renal ACE2 expression in human kidney disease Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International urology and nephrology Angiotensin-converting enzyme 2 activity in patients with chronic kidney disease ACE2 alterations in kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association -European Renal Association Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme: Implications for Albuminuria in Diabetes Endothelial cell infection and endotheliitis in COVID-19 COVID-19: the vasculature unleashed The role of inflammatory cytokines in diabetes and its complications Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians Hypercoagulability of COVID-19 patients in Intensive Care Unit Thromboelastography Findings and other Parameters of Hemostasis Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. Thrombosis and haemostasis COVID-19 Coagulopathy in Caucasian patients Type 2 diabetes: principles of pathogenesis and therapy Innate immunity, insulin resistance and type 2 diabetes NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X Inflammation and insulin resistance Type 2 diabetes as an inflammatory disease COVID-19: consider cytokine storm syndromes and immunosuppression Association of inflammatory markers with the severity of COVID-19 Obesity, inflammation, and insulin resistance Inflammation and Activated Innate Immunity in the Pathogenesis of Type 2 Diabetes Is type II diabetes mellitus a disease of the innate immune system? Diabetes and infection: is there a link?--A mini-review Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology Cytokine storm and sepsis disease pathogenesis The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) The complement system in COVID-19: friend and foe? JCI Insight Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Clinical and immunological features of severe and moderate coronavirus disease 2019 Practical recommendations for the management of diabetes in patients with COVID-19 Hyperglycemia and the worse prognosis of COVID-19. Why a fast blood glucose control should be mandatory. Diabetes research and clinical practice The mechanisms of action of metformin AMPK: a balancer of the reninangiotensin system Chapter 25 -Serine and Threonine Phosphorylation Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis Pioglitazone attenuates lung injury by modulating adipose inflammation Role of CD26/dipeptidyl peptidase IV in human T cell activation and function COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes research and clinical practice Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control Hypothesis for the control of COVID-19 acute lung injury with Glucagon like peptide-1 (GLP1) Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality Effects of ibuprofen on a porcine model of acute respiratory failure Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19 COVID-19 Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19 Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study No funding received. We appreciate Dr. Laure Sayyed-Kassem, Chief of Endocrine Section at Louis Stokes Cleveland VA Medical Center/Case Western Reserve University, for reviewing our manuscript. Aman Rajpal and Leili Rahimi have no disclosures. Faramarz Ismail-Beigi is a consultant for Sanofi and COVANCE. He has grants from the NIH, and has previously received grants from Novo Nordisk; he has shares in Thermalin Insulin.